Introduction
Category | Application | Jurisdiction | Implementation |
---|---|---|---|
Off-patent medicine |
MA for a paediatric use
| Article 30 | 26 July 2007 |
New medicine |
MA that includes a paediatric indication
| Article 7 | 26 July 2008 |
On-patent medicine |
To include a paediatric indication in an existing MA*
| Article 8 | 26 January 2009 |
Methods
Orphan drug designations and marketing authorisations
Paediatric investigation plans
Time course to marketing authorisation
Results
Orphan drug designations and marketing authorisations
Medicine name (active substance) | Paediatric use | Paediatric investigation plan | ||||
---|---|---|---|---|---|---|
Potential paediatric* | On label† | Decision‡ | Condition and age covered by waiver | Ground for waiver | Expected date of completion § | |
Elaprase (idursulfase)
| Yes | All | PW | Mucopolysaccharidosis II (Hunter syndrome) (Girls birth to < 18 y) | Condition does not occur in the specified paediatric subset | December 2015 |
Exjade¶ (deferasirox)
| Yes | 2 | PW | Chronic iron overload requiring chelation therapy (birth to < 2 years) | No significant therapeutic benefit | June 2015 |
Glivec* (imatinib)
| Yes | 1 | PW | Pulmonary arterial hypertension (PAH) (birth to <6 months) | Likely ineffective | May 2013: PIP completed |
Philadelphia chromosome (BCR-ABL translocation) - positive chronic myeloid leukaemia (birth to <18 years) | No significant therapeutic benefit | |||||
Treatment of Philadelphia chromosome (BCR-ABL translocation) - positive acute lymphoblastic leukaemia (birth to < 1 year). | Condition does not occur in the specified paediatric subset | |||||
Ilaris (canakinumab)
| Yes | 2 | PW | Juvenile idiopathic arthritis (birth to < 24 months) | Condition does not occur in the specified paediatric subset and no significant therapeutic benefit | June 2015 |
Cryopyrin Associated Periodic Syndromes (CAPS) including: FCAS, FCU, MWS, NOMID and CINCA* (birth to < 28 days) | No significant therapeutic benefit | |||||
Inovelon (rufinamide)
| Yes | 4 | PW | Lennox-Gastaut syndrome (birth to < 12 months and from 4 to <18 years) | Condition does not occur in the specified paediatric subset and no significant therapeutic benefit | September 2017 |
Kuvan (sapropterin dihydrochloride)
| Yes | 4 | PW | Hyperphenylalaninemia (4 to < 18 years) | No significant therapeutic benefit | January 2014 |
Mozobil (Plerixafor)
| Yes | All | PW | Myelosuppression caused by chemotherapy to treat malignant disorders, which requires an autologous haematopoietic stem cell transplant (birth to < 12 months ) | No significant therapeutic benefit | June 2017 |
Novothirtheen (catridecacog)
| Yes | 6 | PW | Prevention of bleeding during surgical interventions in congenital factor XIII A-subunit deficiency and treatment of bleeding in congenital factor XIII A-subunit deficiency (birth to <18 years) | Condition does not occur in the specified paediatric subset | December 2015 |
For the prevention of bleeding in congenital factor XIII A-subunit deficiency (birth to <1 year) | No significant therapeutic benefit | |||||
Tobi Podhaler (tobramycin)
| Yes | 6 | PW | Pseudomonas aeruginosa pulmonary infection/colonisation in patients with cystic fibrosis (birth to < 3 months) | Likely unsafe and no significant therapeutic benefit | September 2015 |
Tracleer¶ (bosentan monohydrate)
| Yes | 3 | PW | Systemic sclerosis and of interstitial pulmonary (birth to < 18 years) | Condition does not occur in the specified paediatric subset | December 2013 |
Pulmonary arterial hypertension (PAH) (from 28 days to < 3 months and from 12 – 18 years) | No significant therapeutic benefit | |||||
Votubia (everolimus)
| Yes | 3 | PW | Angiomyolipoma (birth to < 18 years) | Condition does not occur in the specified paediatric subset | March 2020 |
Subependymal giant cell astrocytoma and tuberous Sclerosis Complex (NA) | NA | |||||
Vpriv (velaglucerase alfa)
| Yes | 3 | PW | Gaucher Disease, Type 2 (birth to < 18 years) | Likely ineffective | July 2015 |
Gaucher Disease, types 1 and 3 (from birth to < 24 months) | No significant therapeutic benefit | |||||
Xagrid¶ (anagrelide)
| Yes | All | PW | Essential Thrombocythaemiaa (birth to < 6 years) | Condition does not occur in the specified paediatric subset | March 2013 |
Kalydeco (ivacaftor)
| Yes | 6 | FP | NA | NA | December 2016 |
Orfadin¶
| Yes | All | FP | NA | NA | May 2013 |
Revatio¶
| Yes | 1 | FP | NA | NA | July 2014 |
Medicine name (active substance) | Paediatric use | Paediatric investigation plan | ||||
---|---|---|---|---|---|---|
Pot paed* | On label† | Decision‡ | Condition and age covered by waiver | Ground for waiver | Expected date of completion | |
Signifor (pasireotide diaspartate)
| Yes | No | PSW | Pituitary dependent Cushing, overproduction of pituitary ACTH, pituitary dependant hyperadrenocorticism and the treatment of acromegaly and pituitary gigantism (birth to <18 y) | No significant therapeutic benefit | Not applicable |
Vyndaqel (Tafamidis)
| Yes | No | PSW | Neuropathic heredofamilial (birth to <18 y) | No significant therapeutic benefit | Not applicable |
Adcetris (brentuximab vedotin)
| Yes | No | PW | Hodgkin (birth to < 5 y); Anaplastic large cell lymphoma (birth to < 2y) | Both conditions do not occur in the specified paediatric subset | December 2018 |
Bronchitol (mannitol)
| Yes | No | PW | Cystic Fibrosis with pulmonary disease (birth to <6y) | No significant therapeutic benefit | April 2011 |
Cayston (aztreonam lysine)
| Yes | No | PW | Treatment of gram-negative endobronchial infection in bronchiectasis patients (birth to <18 y) | No significant therapeutic benefit | October 2016 |
Treatment of Pseudomonas aeruginosa (PA) pulmonary infection/colonisation in patients with cystic fibrosis (CF) (birth to <3 months) | No significant therapeutic benefit | |||||
Dacogen (decitabine)
| Yes | No | PW | Acute myeloid leukaemia (birth to < 28 days) | No significant therapeutic benefit | July 2021 |
Firazyr (icatibant)
| Yes | No | PW | ACE inhibitor-induced angioedema (birth to < 18) | No significant therapeutic benefit | December 2017 |
Hereditary angioedema (birth to < 2 years | No significant therapeutic benefit | |||||
Glybera (alipogene tiparvovec)
| Yes | No | PW | Hyperchylomicronaemia (birth to < 2 years) | Likely unsafe | December 2021 |
Iclusig (ponatinib)
| Yes | No | PW | Chronic myeloid leukaemia (birth to <1y) | Condition does not occur in the specified paediatric subset | December 2020 |
Acute lymphoblastic leukaemia (birth to <1 y) | No significant therapeutic benefit | |||||
Nplate (romiplostim)
| Yes | No | PW | Disease-related thrombocytopenia in myelodysplastic syndrome (birth to <18 years) | Likely unsafe | December 2014 |
Immune thrombocytopenia (birth to <1 y) | No significant therapeutic benefit | |||||
Plenadren (hydrocortisone)
| Yes | No | PW | Adrenocortical Insufficiency (6 years to < 18 y) | No significant therapeutic benefit | October 2016 |
Revestive (Teduglutide)
| Yes | No | PW | Short bowel syndrome (birth to < 4 months) | No significant therapeutic benefit | February 2017 |
Revolade (eltrombopag olamine)
| Yes | No | PW | Idiopathic Thrombocytopenia Purpura (birth to <1 y) Secondary thrombocytopenia: NA | Condition does not occur in the specified paediatric subset | December 2019 |
Soliris (eculizumab)
| Yes | No | PW | Paroxysmal Nocturnal Haemoglobinuria (PNH) (birth to < 2 y) | Condition does not occur in the specified paediatric subset | June 2019 |
STEC-HUS patients: NA AHUS: NA | Conditions do not occur in the specified paediatric subset | |||||
Sprycel§ (Dasatinib)
| Yes | No | PW | Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia (0-1y) and Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia (0-1y) | Condition does not occur in the specified paediatric subset | June 2018 |
Sutent§
| Yes | No | PW | Gastro-intestinal stromal tumour (0-6y) | Condition does not occur in the specified paediatric subset | June 2014 |
NexoBrid (concentrate of proteolytic enzymes enriched in bromelain)
| Yes | No | FP | NA | NA | March 2019 |
Medicine name (active substance) | Paediatric use | Paediatric investigation plan | ||||
---|---|---|---|---|---|---|
Potential paediatric* | On label† | Decision‡ | Condition and age covered by waiver | Ground for waiver | Expected date of completion PIP for remaining population | |
Arzerra (ofatumumab)
| No | No | CW | Chronic lymphocytic leukaemia (birth to <18y) | Class waiver | NA |
Imnovid (pomalidomide)
| No | No | CW | Multiple myeloma (birth to <18y) | Class waiver | NA |
Jakavi (ruxolitinib)
| No | No | CW | Myeolofibrosis (birth to <18y) | Class waiver | NA |
Thalidomide Celgene (thalidomide)
| No | No | CW | Multiple myeloma (birth to <18y ) | Class waiver | NA |
Afinitor (everolimus)
| No | No | PSW | Renal cell carcinoma and pancreatic neuroendocrine tumour (birth to <18y) | Condition occurs only in adult populations | NA |
Esbriet (pirfenidone)
| No | No | PSW | Idiopathic Pulmonary Fibrosis (birth to <18y) | Condition occurs only in adult populations | NA |
Nexavar
§
(Sorafenib)
| No | No | PSW | Differentiated thyroid cancer (birth to <18y) | No significant therapeutic benefit over existing treatments for paediatric patients. | NA |
Revlimid (lenalidomide)
| No | No | PSW | Multiple myeloma and myelodysplastic syndromes (birth to <18 y) | Likely unsafe | NA |
Torisel (temsirolimus)
| No | No | PSW | For the treatment of mantle-cell lymphoma for all subsets of the paediatric | Condition occurs only in adult populations | NA |
Bosulif (bosutinib)
| No | No | PW | Chronic myeloid leukaemia (birth to <10 y) | Condition occurs only in adult populations | December 2016 |
Tasigna (Nilotinib)
| No | No | PW | Gastro-intestinal stromal tumour (0-18y) and chronic myeloid leukaemia (0-1y) | No significant therapeutic benefit | September 2015 |
Volibris (ambrisentan)
| No | No | PW | Pulmonary arterial hypertension (0-1y) | Likely unsafe | December 2016 |
Paediatric investigation plans
Measure | N |
---|---|
Quality | |
- Development of age appropriate formulation | 14 |
- Assessment of acceptability/ palatability | 2 |
- Bioequivalence | 1 |
- Microbiological testing | 2 |
Total
|
19
|
Non-clinical | |
- Juvenile toxicity study | 20 |
- Other | 8 |
Total
|
28
|
Clinical | |
- Meta-analysis | 1 |
- Randomised, double blind, placebo controlled | 25 |
- Comparative, open label | 20 |
- Uncontrolled | 41 |
- Observational | 3 |
- Bioequivalence/ bioavailability | 5 |
- (PB)PK | 2 |
- Pooled data | 3 |
- Extrapolation | 3 |
- Other | 1 |
Total
|
104
|
Time course to marketing authorisation
Medicine name | Active substance | Indication | Age range | Authorisation date | Status |
---|---|---|---|---|---|
Fabrazyme
| Agalsidase beta | Fabry disease (galactosidase-A deficiency) | 8 years and older | 03/08/2001 | End of marketing exclusivity |
Replagal
| Agalsidase alpha | Fabry disease (galactosidase-A deficiency) | 7 years and older | 03/08/2001 | Authorised under exceptional circumstance, end of marketing exclusivity |
Glivec
| Imatinib | Chronic myeloid leukaemia | > 1 and >2 years | 07/11/2001 | Withdrawn OD status |
Tracleer
| Bosentan monohydrate | Pulmonary arterial hypertension (PAH) | 2 years and older | 15/05/2002 | Authorised |
Zavesca
| Miglustat | Niemann-Pick type-C disease | Children* and adults | 20/11/2002 | Authorised |
Carbaglu
| Carglumic acid | Hyperammonaemia due to - N-acetylglutamate-synthase (NAGS) primary deficiency | As early as the first day of life | 24/01/2003 | Authorised, end of marketing exclusivity for NAGS |
- isovaleric acidaemia | |||||
- methymalonic acidaemia | |||||
- propionic acidaemia | |||||
Aldurazyme
| Laronidase | Mucopolysaccharidosis I (alpha-L-iduronidase deficiency) | Children* and adults | 10/06/2003 | Authorised under exceptional circumstance, end of marketing exclusivity |
Busilvex
| Busulfan | Conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) | Newborn and older | 09/07/2003 | End of marketing exclusivity |
Lysodren
| Mitotane | Advanced adrenal cortical carcinoma | Children** and adults | 28/04/2004 | Authorised |
Pedea
| Ibuprofen | Patent ductus arteriosus | Premature newborns | 29/07/2004 | Authorised |
Wilzin
| Zinc | Wilson’s disease | One year and older | 13/10/2004 | Authorised |
Xagrid
| Anagrelide | Essential thrombocythaemia | Children** and adults | 16/11/2004 | Authorised under exceptional circumstances |
Orfadin
| Nitisinone | Hereditary tyrosinaemia type 1 (HT-1) | Children* and adults | 21/02/2005 | Authorised |
Revatio
| Sildenafil | Pulmonary arterial hypertension | one year and older | 28/10/2005 | Authorised |
Naglazyme
| Galsulfase | Mucopolysaccharidosis VI (N-acetylgalactosamine-4-sulfatase deficiency; Maroteaux-Lamy syndrome) | Children* and adults | 24/01/2006 | Authorised under exceptional circumstances |
Myozyme
| Alglucosidase alpha | Pompe disease (acid-α-glucosidase deficiency) | Children of all ages and adults | 29/03/2006 | Authorised |
Evoltra
| Clofarabine | Acute lymphoblastic leukaemia | 1-21 years | 29/05/2006 | Authorised under exceptional circumstances |
Exjade
| Deferasirox | Beta thalassaemia major with iron overload | 2 years and older | 28/08/2006 | Authorised |
Diacomit
| Stiripentol | Severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) | 3 years and older | 04/01/2007 | Conditional approval |
Elaprase
| Idursulfase | Hunter syndrome (mucopolysaccharidosis II) | 5 years and older | 08/01/2007 | Authorised under exceptional circumstances |
Inovelon
| Rufinamide | Lennox-Gastaut syndrome | 4 years and older | 16/01/2007 | Authorised |
Cystadane
| Betaine anhydrous | Homocystinuria | Children* and adults | 15/02/2007 | Authorised |
Soliris
| Eculizumab | Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS) | Children* and adults | 20/06/2007 | Authorised |
Siklos
| Hydroxycarbamide | Sickle-cell syndrome | 2 years and older | 29/06/2007 | Authorised |
Increlex
| Mecasermin | Primary insulin-like-growth-factor-1 deficiency (primary IGFD) | 2 to 18 years | 03/08/2007 | Authorised under exceptional circumstances |
Atriance
| Nelarabine | Acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) | Children* and adults | 22/08/2007 | Authorised under exceptional circumstances |
Kuvan
| Sapropterin dihydrochloride | Phenylketonuria (PKU) and tetrahydrobiopterin (BH4) deficiency | 4 years and older | 02/12/2008 | Authorised |
Mepact
| Mifamurtide | Osteosarcoma | 2 to 30 years | 06/03/2009 | Authorised |
Peyona
| Caffeine citrate | Primary apnoea | Premature newborns | 02/07/2009 | Authorised |
Mozobil
| Plerixafor | Lymphoma and multiple myeloma | Children** and adults | 31/07/2009 | Authorised |
Cayston
| Aztreonam lysine | Cystic fibrosis (CF) | 6 years and older | 21/09/2009 | Authorised |
Ilaris
| Canakinumab | Cryopyrin-Associated Periodic Syndromes (CAPS), and Systemic Juvenile Idiopathic Arthritis (SJIA) | 2 years and older | 23/10/2009 | Authorised under exceptional circumstances, withdrawn OD status |
Tepadina
| Thiotepa | Allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) | Children* and adults | 15/03/2010 | Authorised |
Vpriv
| Velaglucerase alpha | Type-1 Gaucher disease | >2 years | 26/08/2010 | Authorised |
Tobi Podhaler
| Tobramycin | Cystic fibrosis | 6 years and older | 20/07/2011 | Authorised |
Votubia
| Everolimus | Subependymal giant-cell astrocytoma (SEGA) associated with tuberous-sclerosis complex (TSC) | 3 years and older | 02/09/2011 | Conditional approval |
Xaluprine
| 6-Mercaptopurine monohydrate | Acute lymphoblastic leukaemia (ALL) | Children* and adults | 09/03/2012 | Authorised |
Kalydeco
| Ivacaftor | Cystic fibrosis (CF) with G551D mutation in the CFTR gene | 6 years and older | 23/07/2012 | Authorised |
Novothirteen
| Catridecacog | Congenital factor-XIII-A-subunit deficiency | 6 years and above | 03/09/2012 | Withdrawn OD status |
Procysbi
| Mercaptamine bitartrate | Nephropathic cystinosis | Children* and adults | 06/09/2013 | Authorised |
Orphacol
| Cholic acid | Inborn errors in primary bile-acid synthesis due to 3-hydroxy-5-C27-steroid oxidoreductase deficiency or 4-3-oxosteroid-5-reductase deficiency | One month and older | 12/09/2013 | Authorised under exceptional circumstances |
Defitelio
| Defibrotide | Severe hepatic veno-occlusive disease (VOD) in haematopoietic stem-cell transplantation (HSCT) therapy | One month and older | 18/10/2013 | Authorised under exceptional circumstances |